Back to News
Market Impact: 0.15
PAVmed Inc. Subsidiary Lucid Diagnostics Raises $15.0 million in Series C Preferred Stock Offering
Source: Nasdaq
Company FundamentalsPrivate Markets & Venture
Effective October 21, 2026, Lucid Diagnostics Inc., a PAVmed Inc. subsidiary, entered into subscription agreements with certain accredited investors for the sale of 15,000 shares of newly designated Series C stock. The provided text does not specify the proceeds, share price, or remaining transaction terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
LUCD0.10
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle
- AI Research Tools With Exact Source Citations